Bristol Myers Squibb (BMY) Other Non-Current Assets (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Other Non-Current Assets data on file, last reported at $6.1 billion in Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $6.1 billion, up 3.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.1 billion (up 3.68% YoY), and the FY2025 annual result was $6.5 billion, up 6.04% from the prior year.
• Other Non-Current Assets slipped to $6.1 billion in Q1 2026 per BMY's latest filing, from $6.5 billion in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $6.5 billion in Q4 2025 and troughed at $53.0 million in Q1 2023.
• A 5-year average of $3.9 billion and a median of $5.9 billion in 2025 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets sank 97.06% in 2022, then soared 11354.72% in 2024.
• A 5-year view of Other Non-Current Assets shows it stood at $4.9 billion in 2022, then advanced by 8.7% to $5.4 billion in 2023, then rose by 13.69% to $6.1 billion in 2024, then advanced by 6.04% to $6.5 billion in 2025, then slipped by 6.05% to $6.1 billion in 2026.
• Business Quant data shows BMY's Other Non-Current Assets at $6.1 billion in Q1 2026, $6.5 billion in Q4 2025, and $6.3 billion in Q3 2025.